Видео ютуба по тегу Prima Biomed

Prima Biomed
Prima Biomed
Prima BioMed CVac - Demo
Prima BioMed CVac - Demo
Prima BioMed Top # 5 Facts
Prima BioMed Top # 5 Facts
Prima BioMed (ASX: PRR)
Prima BioMed (ASX: PRR)
SECFilings.com Executive Interview | Prima Biomed (NASDAQ: PBMD)
SECFilings.com Executive Interview | Prima Biomed (NASDAQ: PBMD)
Prima BioMed Ltd. - Developing Personalized Immunocellular Therapeutics
Prima BioMed Ltd. - Developing Personalized Immunocellular Therapeutics
Opening bell ceremony of Prima BioMed on NASDAQ
Opening bell ceremony of Prima BioMed on NASDAQ
CEO ROADSHOW | Interview | Prima Biomed (NASDAQ: PBMD)
CEO ROADSHOW | Interview | Prima Biomed (NASDAQ: PBMD)
ABN Newswire Video Report Feb 21, 2011: Prima BioMed (ASX:PRR)
ABN Newswire Video Report Feb 21, 2011: Prima BioMed (ASX:PRR)
Matthew Lehman CEO of Prima BioMed Ltd. Interviewed Live on Clear Channel The Traders Network Show
Matthew Lehman CEO of Prima BioMed Ltd. Interviewed Live on Clear Channel The Traders Network Show
Matthew Lehman CEO of Prima BioMed Ltd. Interviewed Live on Clear Channel The Traders Network Show
Matthew Lehman CEO of Prima BioMed Ltd. Interviewed Live on Clear Channel The Traders Network Show
$PBMD News: Prima Biomed LTD CVac Shows Clear Trend for Overall Survival Benefit
$PBMD News: Prima Biomed LTD CVac Shows Clear Trend for Overall Survival Benefit
Matthew Lehman CEO of Prima BioMed Ltd. Interviewed Live on Clear Channel the Traders Network Show
Matthew Lehman CEO of Prima BioMed Ltd. Interviewed Live on Clear Channel the Traders Network Show
3D Animation Krebsimmuntherapie
3D Animation Krebsimmuntherapie
AIPAC: Final results of Phase IIb trial of eftilagimod alpha vs placebo with chemo for HR+ HER2- MBC
AIPAC: Final results of Phase IIb trial of eftilagimod alpha vs placebo with chemo for HR+ HER2- MBC
Immutep CEO Marc Voigt - the next phase of immunotherapy - CEO Series
Immutep CEO Marc Voigt - the next phase of immunotherapy - CEO Series
Immutep (ASX:IMM, NASDAQ:IMMP) Global Webcast Presentation at SITC 2022
Immutep (ASX:IMM, NASDAQ:IMMP) Global Webcast Presentation at SITC 2022
Immutep's (IMMP) High-Stakes Moment
Immutep's (IMMP) High-Stakes Moment
Immutep (ASX:IMM, NASDAQ:IMMP) reports first subject dosed in autoimmune disease study
Immutep (ASX:IMM, NASDAQ:IMMP) reports first subject dosed in autoimmune disease study